• Massimo Francesco Piepoli, Elisabetta Salvioni, Ugo Corrà, Francesco Doni, Alice Bonomi, Rocco La Gioia, Giuseppe Limongelli, Stefania Paolillo, Gianfranco Sinagra, Angela B Scardovi, Rosa Raimondo, Michele Emdin, Federica Re, Mariantonietta Cicoira, Michele Correale, Roberto Badagliacca, Francesco Clemenza, Carlo Lombardi, and Piergiuseppe Agostoni.
• UOC Cardiologia, G da Saliceto Hospital, Piacenza, Italy; Department of Cardiology, University of Foggia, Foggia, Italy.
• Eur. J. Intern. Med. 2020 Feb 1; 72: 47-52.

BackgroundHyperuricemia prognostic impact on clinical outcomes in chronic heart failure (HF) patients has been investigated with inconclusive results.ObjectivesAim of the study was to evaluate the prognostic impact of serum uric acid (SUA) on long-term clinical outcomes in HF.MethodsAn analysis of MECKI (Metabolic Exercise Cardiac Kidney Index) database, with median follow-up of 3.4 years.ResultsRelation between SUA and all-cause/ cardiovascular (CV) deaths have been analysed in 4,577 patients (3,688 males, age 62.7 ± 12.9 years), with reduced ejection fraction HF (35 ± 11%), peakVO2 1151 ± 440 ml/min; NYHA class I-II (72.6%), III-IV (27.4%). SUA was associated with increased total and CV mortality (HR 1.120 and HR 1.128, respectively p < 0.0001), also after adjustment for peakVO2, VE/VCO2 slope, diuretic use and MECKI score. SUA was significantly associated with CV mortality only in NYHA class I-II (HR 1.17, p < 0.0001) while there was no association in class III-IV (HR 1.03, p = NS). No prognostic added values of SUA with respect to the MECKI score was observed at the ROC analysis.ConclusionsSUA is confirmed to be associated with increased mortality, but in less severe HF only. However SUA did not show additional prognostic power to the MECKI score.Copyright © 2019. Published by Elsevier B.V.

13 keywords...

hide…